3 completed, 2 recruiting, 1 not yet recruiting. 6 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 3, Recruiting 2, Not yet recruiting 1 |
| Phase 2 | 2 | Completed 1, Not yet recruiting 1 |
Follow Vaccine: new trials by email Literature Review of Vaccine trials Research Report on Vaccine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Trial Phase I/IIa to Evaluate the Safety and Immunogenicity of StreptInCor StrepIncor, Placebo - Rheumatic Heart Disease, Rheumatic Heart Disease in Children | Phase 1 / Phase 2 | Not yet recruiting | University of Sao Paulo General Hospital | 60 | 2025-10-01 | 2025-07-22 |
| Safety and Immunogenicity of a Self-Amplifying RNA Vaccine Against Crimean-Congo Hemorrhagic Fever 10 ug HDT 321, 25ug HDT-321, 50ug HDT-321 - Vaccine, Crimean-Congo Hemorrhagic Fever | Phase 1 | Recruiting | HDT Bio | 48 | 2025-07-10 | 2025-07-28 |
| An Open-label, Dose-finding, Phase I Study to Evaluate the Safety and Immunogenicity of a Bivalent Klebsiella Pneumoniae Vaccine (CHO-V08) in Healthy Adults Glyconjugate Klebsiella pneumoniae bivalent vaccine - Klebsiella Pneumoniae Infection, Vaccine | Phase 1 | Recruiting | Cho Pharma Inc. | 40 | 2025-06-26 | 2025-06-27 |
| This is a Double-blind, Placebo-controlled, Randomized Study of the Tolerability, Safety and Immunogenicity of an Inactivated Whole Virion Concentrated Purified Vaccine (CoviVac) Against Covid-19 Vaccine for intramuscular injection, Placebo comparator (without active ingredient) for intramuscular injection - Coronavirus Infections, Vaccine | Phase 1 / Phase 2 | Completed | Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products | 400 | 2020-10-03 | 2021-11-12 |
| Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine cH8/1N1 LAIV, AS03-adjuvanted cH5/1N1 IIV, cH5/1N1 IIV - Influenza, Vaccine | Phase 1 | Completed | PATH | 65 | 2017-10-10 | 2021-02-21 |
| Open-label Safety and Tolerability Study of CoVaccine HT™ in Healthy Volunteers CoVaccine HT - Vaccine | Phase 1 | Completed | BTG International Inc. | 50 | 2009-11-01 | 2014-09-15 |
COVID-19 (1) · Coronavirus Infections (1) · Hemorrhagic Fever, Crimean (1) · Hypertension (1) · Influenza, Human (1) · Rheumatic Diseases (1) · Rheumatic Fever (1) · Rheumatic Heart Disease (1)
Infections (4) · RNA Virus Infections (3) · Virus Diseases (3) · Cardiovascular Diseases (2) · Respiratory Tract Diseases (2) · Respiratory Tract Infections (2) · Arbovirus Infections (1) · Arthritis (1) · Bacterial Infections (1) · Bacterial Infections and Mycoses (1) · Bunyaviridae Infections (1) · Connective Tissue Diseases (1) · Coronaviridae Infections (1) · Gram-Positive Bacterial Infections (1) · Heart Diseases (1)
AS03 adjuvant (1) · Injections, Intramuscular (1) · Saline Solution (1) · Vaccines (1)
BTG International Inc. (1) · Cho Pharma Inc. (1) · Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products (1) · HDT Bio (1) · PATH (1) · University of Sao Paulo General Hospital (1)
United States (2) · Brazil (1) · Russia (1) · Taiwan (1) · United Kingdom (1)
Darren Wilbraham, MB., BS (1) · David Bernstein, MD (1) · Jeffrey Guptill, MD (1) · Jorge E Kalil Filho, Full Professor, MD, PhD (1) · Malcolm Duthie, PhD (1)